Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

PURPOSE: The antibody–drug conjugate enfortumab vedotin (EV) releases a cytotoxic agent into tumor cells via binding to the membrane receptor NECTIN-4. EV was recently approved for patients with metastatic urothelial carcinoma (mUC) without prior assessment of the tumor receptor status as ubiquitous...

Descripción completa

Detalles Bibliográficos
Autores principales: Klümper, Niklas, Ralser, Damian J., Ellinger, Jörg, Roghmann, Florian, Albrecht, Julia, Below, Eduard, Alajati, Abdullah, Sikic, Danijel, Breyer, Johannes, Bolenz, Christian, Zengerling, Friedemann, Erben, Philipp, Schwamborn, Kristina, Wirtz, Ralph M., Horn, Thomas, Nagy, Dora, Toma, Marieta, Kristiansen, Glen, Büttner, Thomas, Hahn, Oliver, Grünwald, Viktor, Darr, Christopher, Erne, Eva, Rausch, Steffen, Bedke, Jens, Schlack, Katrin, Abbas, Mahmoud, Zschäbitz, Stefanie, Schwab, Constantin, Mustea, Alexander, Adam, Patrick, Manseck, Andreas, Wullich, Bernd, Ritter, Manuel, Hartmann, Arndt, Gschwend, Jürgen, Weichert, Wilko, Erlmeier, Franziska, Hölzel, Michael, Eckstein, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102834/
https://www.ncbi.nlm.nih.gov/pubmed/36534531
http://dx.doi.org/10.1158/1078-0432.CCR-22-1764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102834/
https://www.ncbi.nlm.nih.gov/pubmed/36534531
http://dx.doi.org/10.1158/1078-0432.CCR-22-1764

Ejemplares similares